Molecular characterization of carbapenem resistant isolates of Acinetobacter baumannii in an intensive care unit of a tertiary care centre at central India

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 5, 2014, Pages 38-40

  Khajuria, Atul ^a   Praharaj, Ashokkumar ^a   Kumar, Mahadevan ^b   Grover, Naveen ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Baumannii; Carbapenem; Metallo beta lactamase; Multidrug resistant

Indexed keywords

AMIKACIN; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; NETILMICIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM EXAMINATION; BACTERIUM IDENTIFICATION; COMBINED DISC SYNERGY TEST; CONTROLLED STUDY; DISK DIFFUSION; DNA SEQUENCE; DOUBLE DISC SYNERGY TEST; EPSILOMETER TEST; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; INDIA; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SCREENING TEST; TERTIARY CARE CENTER;

EID: 84901263840     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/7749.4398     Document Type: Article

References (20)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51: 3471-84.
2. Ben Othman A, Zribi M, Masmoudi A, Abdellatif S, Ben Lakhal S, Fendri C. Multiresistance and endemic status of Acinetobacter baumannii associated with nosocomial infections in a tunisian hospital: a critical situation in the intensive care units. Braz J Microbiol. 2011; 42:415-22.
3. Bergogne-Berezin E, Towner KJ. Acinetobacter spp.as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996; 9:148-65.
4. Young DM. & Ornston LN. Functions of the mismatch repair gene mutS fromAcinetobacter sp. strain ADP1. Journal of Bacteriology. 2001;183: 6822-31.
5. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing OXA-23 enzymes in Curitiba, Brazil. J Clin Microbiol. 2003. 41 (7), 3403-6.
6. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2003;51: 565-74.
7. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A, et al. High prevalence of OXA-51-type class D Beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centers. Journal of Antimicrobial Chemotherapy. 2006; 58:537-42.
8. Brown S & Amyes S. OXA-β-lactamases in Acinetobacter: the story so far. Journal of Antimicrobial Chemotherapy. 2006;57:1-3.
9. Roca I, Espinal P, Vila-Farrés X, Vila J. The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol. 2012; 3: 148.
10. Collee JG, Miles RS, Wan B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A editor. Mackie and Mc Cartney Practical Medical Microbiology. 14th ed. Edinburgh: Churchill Livingstone; 1996;p. 131-50.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: twenty second Informational Supplement M100-S22. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA, 2012.
12. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14from India. Antimicrobial Agents and Chemotherapy. 2009; 53:5046-54.
13. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006; 50(12): 4114-23.
14. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006; 27(4): 351-3.
15. Koeleman J., Stoof J, Bijl M, Grauls C and Savelkoul P. Identification of epidemic strains of Acinetobacter baumannii by Integrase Gene PCR. Journal of clinical microbiology. 2001; 39:8-13.
16. Kuo HY, Yang CM, Lin MF, Cheng WL, Tien N, Liou ML. Distribution of blaOXA-carrying imipenem-resistant Acinetobacter spp. in 3 hospitals in Taiwan. Diagn Microbiol Infect Dis. 2010;66(2):195-9.
17. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil" Int J Antimicrob Agents. 2009;34:25-8.
18. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii:mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826-36.Review.
19. Park S, Kim HS, Lee KM, Yoo JS, Yoo JI, Lee YS, et al. Molecular and epidemiological characterization of carbapenem-resistant Acinetobacter baumannii in non-tertiary Korean hospitals. Yonsei Med J. 2013;54(1):177-82.
20. Mezzatesta ML, D'Andrea MM, Migliavacca R, Giani T, Gona F, Nucleo E, et al. Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy. Clin Microbiol Infect. 2012; 18(2):160-6.